Omidenepag Isopropyl
Omidenepag Isopropyl Basic information
- Product Name:
- Omidenepag Isopropyl
- Synonyms:
-
- Omidenepag Isopropyl
- OMDI
- Glycine, N-[6-[[[[4-(1H-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]-2-pyridinyl]-, 1-methylethyl ester
- Isopropyl (6-((N-(4-(1H-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)pyridin-2-yl)glycinate
- CAS:
- 1187451-19-9
- MF:
- C26H28N6O4S
- MW:
- 520.6
- Mol File:
- 1187451-19-9.mol
Omidenepag Isopropyl Chemical Properties
- solubility
- DMSO: Sparingly soluble: 1-10 mg/ml
- form
- Solid
- color
- White to off-white
- InChIKey
- VIQCWEGEHRBLAC-UHFFFAOYSA-N
- SMILES
- C(OC(C)C)(=O)CNC1=NC(CN(CC2=CC=C(N3C=CC=N3)C=C2)S(C2=CC=CN=C2)(=O)=O)=CC=C1
Omidenepag Isopropyl Usage And Synthesis
Uses
Omidenepag Isopropyl is a derivative of Omidenepag (O635205) which is a novel selective, non-prostanoid EP2 receptor agonist for the treatment of Glaucoma:
in vivo
Omidenepag isopropyl at 0.0001%, 0.001%, or 0.01%, Xalatan, or vehicle was topically administered to one eye in ocular normotensive monkeys. IOP change after drug administration was compared to the predosing baseline value established on day 1. Omidenepag isopropyl also shows significant and dose-dependent IOP-lowering effects at doses of 0.0001%, 0.001%, and 0.01% in ocular normotensive monkeys, with mean maximal IOP reductions of 2.4 ± 0.6, 7.6 ± 1.7, and 13.3 ± 1.2 mm Hg at each tested concentration, respectively. The significant decreases in IOP for 0.001% and 0.01% OMDI at time 0 of day 7. Omidenepag isopropyl is hydrolyzed in the eye to Omidenepag (OMD), an EP2 receptor agonist , with a significant ocular hypotensive effect in both ocular normotensive and hypertensive animal models[1].
In ocular hypertensive monkeys finds that Omidenepag isopropyl lowers IOP by increasing both trabecular outflow facility and uveoscleral outflow[2].
IC 50
EP2
References
[1] RYO IWAMURA*. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl[J]. Journal of Medicinal Chemistry, 2018, 61 15: 6869-6891. DOI: 10.1021/acs.jmedchem.8b00808
[2] TOMOKO KIRIHARA. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.[J]. Investigative ophthalmology & visual science, 2018, 59 1: 145-153. DOI: 10.1167/iovs.17-22745
Omidenepag IsopropylSupplier
- Tel
- 027-81525288 18086100502
- linwell@126.com
- Tel
- 18149758185 18149758185;
- sales-cpd@caerulumpharma.com
- Tel
- 021-QQ：65489617 15618227136
- Sales@ATKchemical.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 86-571-88216897,88216896 13588875226
- sales@hzclap.com